This EVERSANA white paper explores the commercialization challenges and opportunities of personalized cancer immunotherapies, which tailor treatment to each patient’s unique tumor genetics using mRNA-based technologies. It highlights the promise of these therapies to improve treatment effectiveness, reduce side effects, and enhance long-term immune responses, while discussing leading development efforts by BioNTech and Moderna. The paper also outlines key barriers, including complex manufacturing, scalability, cold-chain logistics, reimbursement, affordability, regulatory requirements, and patient access. It concludes that successful commercialization will require integrated, data-driven strategies, specialized supply chains, coordinated patient services, and agile market access models to

Join for free to read